OSLO, Norway--(BUSINESS WIRE)--Regulatory News:
With reference to stock exchange notifications 22 January and 25 February 2014 and in accordance with the resolution at the Extraordinary General Meeting held today 25 February 2014 shares in DiaGenic ASA will be traded ex subscription rights in connection with the planned rights issue as of tomorrow 26 February 2014.
The subscription period for the rights issue is expected to be from on or about 17 March 2014 to on or about 31 March 2014 at 16:30 hours CET. Trading in the subscription rights is expected to commence on Oslo Børs or about 17 March 2014 and end on or about 28 March 2014 at 16:30 hours (CET).
The subscription price will be NOK 0.50 per new share and each eligible shareholder will be granted 12.25509 subscription rights for each share registered as held by such eligible shareholder as of the record date 28 February 2014.
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company's proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer's disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com
This information was brought to you by Cision http://news.cision.com